DYRK1A: a potential drug target for multiple Down syndrome neuropathologies

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Down syndrome (DS) is the most common genetic cause of intellectual disability, characterized by trisomy of chromosome 21.
• The MNB/DYRK1A gene on chromosome 21 is strongly linked to DS neuropathologies, including cognitive deficits and Alzheimer's-like neurodegeneration.

Purpose of the Study:

• To review the functional complexity of MNB/DYRK1A in the context of Down syndrome.
• To evaluate the efficacy of MNB/DYRK1A inhibitors in reversing DS-associated neurobiological alterations in experimental models.
• To discuss the therapeutic potential and challenges of targeting MNB/DYRK1A for Down syndrome.

Main Methods:

• Literature review focusing on MNB/DYRK1A function and its role in Down syndrome.
• Analysis of studies investigating small-molecule inhibitors of MNB/DYRK1A kinase activity.
• Examination of experimental models demonstrating MNB/DYRK1A-induced neurobiological changes and their reversal.

Main Results:

• MNB/DYRK1A overexpression correlates with key DS neuropathologies like neuronal deficits and cognitive impairment.
• Several MNB/DYRK1A inhibitors have demonstrated the capacity to reverse these DS-like neurobiological alterations in preclinical studies.
• The efficacy of inhibitors varies, highlighting the complexity of targeting MNB/DYRK1A.

Conclusions:

• MNB/DYRK1A is a significant factor in Down syndrome neurobiology and a promising therapeutic target.
• Further research is needed to navigate the functional, molecular, and pharmacological complexities of MNB/DYRK1A for effective therapeutic strategies.
• MNB/DYRK1A-based therapies offer potential but require careful consideration of advantages and drawbacks.